Donman, All those deals were done in a completely different environment. The standard of care for HCV is just about to change completely with a new set of drugs from several manufacturers treating nearly all types of HCV patients. The old notion of what the market is no longer applies.
I am sure the Board would love to get a Gilead/Pharmasset deal done. So would I, so would we all, but the likelihood is we will have to settle for something much less and we will have to convince potential partners that we can deliver a return on investment. The people in large companies that make these investment decisions don't care if a drug works. All they want to know is what market share are we going to get and when and what return on investment will we get. To these people the notion of 'Build it and they will come' is build me a money making machine and I will buy it. BLT and TT-034 have a long way to go before they are money making machines and this is the point that I am trying to make. To be successful we need more than just good results for a Pl/lla trial.
We are at a time in the growth of the company where, more then ever, the right management decisions to be made. Management may have the wherewithal to make these decisions but achieving success is more complicated than just waiting and hoping for good results and, as shareholders we need to be cognisant of this.
Who knows what the next nine months holds for BLT. It will be an exciting time, one way or another, but no matter what the issue of needing more capital won't go away and IMO no pharma is going to drop a bundle of cash in our laps without us have to work hard to convince them part with it.
Add to My Watchlist
What is My Watchlist?